美泊利单抗和门诊鼻息肉切除术治疗慢性鼻窦炎 (CRS) 患者。三臂研究。 (MELYSA)
This randomized, controlled multicenter trial will recruit patients aged 18 to 70 7 years with recurrent nasal polyposis requiring surgery and indication for biologic treatment according to EPOS 2020 guideline. Patients in the Mepolizumab arms will receive 100 mg of subcutaneous mepolizumab every 4 weeks for a total of 12 doses in addition to daily topical corticosteroid treatment.
All study procedures will be performed in five study visits and may take approximately 30 minutes. Clinical assessments include different questionnaires and nasal endoscopy. This trial includes three treatment arms.
- Combined group (In-office nasal polypectomy group with mepolizumab): This group will undergone in-office nasal polypectomy and will receive Mepolizumab.
- Medical group (mepolizumab): This group will receive Mepolizumab.
- Surgical group (In-office nasal polypectomy): This group will undergone in-office nasal polypectomy. The main advantage is that it allows comparison of mepolizumab versus surgery and surgery/mepolizumab versus surgery + mepolizumab, providing more information on the most effective therapeutic approach.
The presence of adverse effects will be assessed in each treatment arm.
研究概览
研究类型
注册 (估计的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
-
Bilbao、西班牙
- Hospital de Curces
-
Jerez de la Frontera、西班牙
- Hospital de Jerez
-
Madrid、西班牙
- Hospital Puerta del Hierro
-
Oviedo、西班牙
- HUCA
-
Seville、西班牙
- Hospital Virgen Macarena
-
Valladolid、西班牙
- Hospital Valladolid
-
-
Spain
-
Santander、Spain、西班牙、39011
- Hospital Universitario Marques de Valdecilla
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Participant 18 years of age or older
- Patients with a diagnosis of CRS with polyposis according to the criteria of the EPOS2020 guideline:
Chronic rhinosinusitis with nasal polyps in adults is defined as presence of two or more symptoms, one of which should be either nasal blockage / obstruction / congestion or nasal discharge (anterior / posterior nasal drip); ± facial pain/pressure; ± reduction or loss of smell; for ≥12 weeks; and either endoscopic signs of nasal polyps, and/or CT changes: mucosal changes within the ostiomeatal complex and/or sinuses.
- Patients with indication for biologic treatment according to the criteria of the EPOS2020 guideline. Presence of bilateral polyps in a patient who had ESS (except in cases where the patient is not fit for surgery, see bellow) and three of the following criteria are required:
- Evidence of type 2 inflammation (tissue eos> 10/hpf* or blood eos>250, OR total IgE> 100).
- Need for systemic corticosteroids or contraindication to systemic steroids (≥ 2 courses per yr, OR long term (>3 months)
- Significantly impaired quality of life (SNOT ≥ 40)
- Significant loss of smell (≥7 VAS)
- Diagnosis of comorbid asthma
- Basal eosinophil count (BEC) ≥300 cells/μL for surgical naïve patients- only those not fit for surgery (major criteria) or for those who have had surgery and have recurrence (minor criteria).
- Patients have been informed and signed consent to participate in the study.
- For those patients not suitable for surgery, the criteria of the EUFOREA guidelines for indication of biological treatment will be used (4 criteria, one of them being ≥300 cells/μL BEC).
Exclusion Criteria:
- Any serious or uncontrolled systemic or psychiatric illness that prevents a correct cognitive or endoscopic assessment or does not advise participation in the study.
- Unilateral localized secondary CRS (odontogenic, fungal ball, tumor).
- Bilateral diffuse secondary CRS (cystic fibrosis; eosinophilic granulomatosis with polyangiitis-S. de Churg-Strauss-; granulomatosis with polyangiitis-S de Wegener-; primary ciliary dyskinesia; selective immunodeficiencies.
- Pregnancy/ breast feeding
- Hypersensitivity to mepolizumab or it's excipients
- Patients unable to complete the questionnaire or follow prescribed treatment.
- Patients who are participating in another clinical trial related to polyposis or asthma.
- Previously documented failure with IL-5/IL-5 receptor biologics
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Combined group
In-office nasal polypectomy group with mepolizumab |
Patients in the Mepolizumab arms will receive 100 mg of subcutaneous mepolizumab every 4 weeks for a total of 12 doses in addition to daily topical corticosteroid treatment This group will undergone in-office nasal polypectomy. |
|
实验性的:Medical group
(mepolizumab) |
Patients in the Mepolizumab arms will receive 100 mg of subcutaneous mepolizumab every 4 weeks for a total of 12 doses in addition to daily topical corticosteroid treatment |
|
有源比较器:Surgical group
In-office nasal polypectomy |
This group will undergone in-office nasal polypectomy. |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
使用鼻窦结果测试 (SNOT-22) 总分相对于基线的变化,将美泊利单抗 + 息肉切除术与美泊利单抗或息肉切除术进行比较
大体时间:长达 52 周
|
长达 52 周
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
4周、6个月、12个月时鼻息肉病严重程度VAS评分的变化
大体时间:长达 52 周
|
长达 52 周
|
|
|
4周、6个月、12个月内镜鼻息肉评分变化
大体时间:长达 52 周
|
长达 52 周
|
|
|
个体 VAS 症状(鼻漏、喉咙粘液、鼻塞和嗅觉)的改善,患者报告的 4 周、6 个月、12 个月结果
大体时间:长达 52 周
|
长达 52 周
|
|
|
研究开始第一个月后第一年不再需要全身性皮质类固醇救援治疗的患者人数
大体时间:长达 52 周
|
长达 52 周
|
|
|
发生美泊利单抗和诊室鼻息肉切除术相关不良事件的参与者人数
大体时间:长达 52 周
|
长达 52 周
|
|
|
Change from baseline in sinonasal outcome test
大体时间:up to 4 and 24 week
|
The minimum value is 0 and maximum value is 110 |
up to 4 and 24 week
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- IDIVAL
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.